PARI LC Plus and PRONEB Ultra Used in Two Perforomist Studies on Improving COPD Therapies
... COPD studies sponsored by DEY LP, PARI's LC Plus
nebulizer and PRONEB compressors (Ultra and Ultra II) were ... researchers chose PARI products as the exclusive
nebulizer systems for recent studies comparing maintenance ... to placebo/tiotropium.
The PARI LC Plus
nebulizer and PARI PRONEB Ultra compressor were used ...
Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)
... once daily for 28 days using an eFlow(R)
nebulizer System (PARI Pharma GmbH), a novel, highly ...
About PARI Pharma and the eFlow (R)
nebulizer System
ARIKACE is delivered by an eFlow
nebulizer System developed by PARI Pharma GmbH. The ...
PARI Pharma Reports Successful Phase Ib Clinical Results for Inhaled Liposomal Cyclosporine A and Gains FDA Orphan Drug Designation for the Prevention and Treatment of Bronchiolitis Obliterans
... for L-CsA, delivered via an Investigational eFlow
nebulizer System, for the prevention and treatment of ... for administration via an Investigational eFlow
nebulizer System without destroying the liposome," stated ... dose of 10mg L-CsA with an Investigational eFlow
nebulizer System would give approximately 14 mg L-CsA/week. ...
PARI Pharma's Nebulized DSCG Shows Results Similar to Inhaled Steroids in Asthma Studies Presented at ATS
... a customized small droplet Investigational eFlow
nebulizer System designed to deliver drugs to the deep ... (MMAD ~ 3.3 microns) Investigational eFlow
nebulizer System has similar effects on asthma control, ... when administered via the Investigational eFlow
nebulizer System," said Prof. Johannes Wildhaber, principal ...
Inspire's Phase 3 CF Trial, Using PARI's Nebulizer & Compressor, Shows Positive Top-Line Results
... inhalation solution
delivered via PARI's LC STAR
nebulizer and PRONEB Ultra compressor for the
treatment of ... The combination of PARI's LC STAR breath-enhanced
nebulizer and PRONEB
Ultra compressor provides for a quick ... the
PARI LC PLUS, and the new PARI LC Sprint
nebulizer line, PARI also
manufactures the award-winning ...
PARI's eFlow Delivers Alnylam RNAi Therapeutic in Phase II Study
... /PRNewswire/ -- An optimized PARI eFlow
platform
nebulizer will be delivering Alnylam's ALN-RSV01 in a Phase ... .
About eFlow
eFlow, an electronic, portable
nebulizer platform, enables extremely
efficient ... vibrating, perforated
membrane. Compared to other
nebulizer systems, eFlow can produce aerosols
with a very ...
PARI Nebulizer & Compressor Used Exclusively in Inspire's Phase 3 CF Trial
... Va., March 10 /PRNewswire/ -- PARI's LC STAR
nebulizer and
PRONEB Ultra II compressor are the exclusive ... Equipment. "Our LC
STAR is a fine particle
nebulizer that enables delivery of aerosols to the
smaller ... .
The combination of PARI's LC STAR
nebulizer and PRONEB Ultra II
compressor provides for a ...
PARI's eFlow Included in Gilead's NDA Submission for Aztreonam Lysine for Inhalation
... 26 /PRNewswire/ -- PARI Pharma's eFlow
electronic
nebulizer was included in Gilead's (Nasdaq: GILD ) recent ... that produce the aerosol mist.
Compared to other
nebulizer systems, eFlow can produce aerosols with a ... inhalation drug development,
including
nebulizer formulation development and optimization, ...
Mpex Pharmaceuticals Presents New Data on MP-376 in Cystic Fibrosis
... of levofloxacin inhaled solution delivered by
an Investigational eFlow
nebulizer System for use in cystic fibrosis (CF)
and chronic obstructive pulmonary ... of MP-376 when
administered by inhalation using an Investigational eFlow
nebulizer System.
All patients were required to be culture positive for P. ...
Mpex Initiates a Phase 2 Clinical Trial of Aerosol MP-376 in the Treatment of Chronic Bacterial Infections in Cystic Fibrosis Patients
... Pseudomonas aeruginosa. Administration of MP-376 with a high
efficiency
nebulizer to the lungs allows for the delivery of high
concentrations of active drug ... Nebulizer, developed by PARI Pharma GmbH. eFlow(R) is a quiet
portable
nebulizer that enables efficient aerosolization of liquid
medications via a ...
Cystic Fibrosis - Orphan Drug Designation for Innovative Treatment Against Lung Infections by Axentis Pharma AG
... proprietary Fluidosomes
technology with the well-established generic drug tobramycin. Utilising
synthetic liposomes containing tobramycin, a standard
nebulizer delivers the
drug directly to the endobronchial sites of infection in cystic fibrosis
patients. This may result in prolonged high local drug ...
Transave Announces Positive Phase II Results for Once-Daily Arikace(TM) in the Treatment of Cystic Fibrosis Patients Who Have Pseudomonas Lung Infections
... Arikace is delivered by a novel inhalation device, the eFlow(R)
Electronic Nebulizer, developed by PARI Pharma GmbH. eFlow is a quiet,
portable
nebulizer that enables efficient aerosolization of liquid
medications, including liposomal formulations such as Arikace, via a
vibrating perforated membrane. ...
Nektar Threraputics Announces Phase 2a Clinical Results Regarding
the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative
Hospital-Acquired Pneumonia Presented at the Annual American
Thoracic Society International Conference
... that provides key advantages over traditional
pneumatic or ultra-sonic
nebulizer delivery.
Hospital-acquired, gram-negative bacterial pneumonia is ... which provides key advantages over traditional
pneumatic or ultra-sonic
nebulizer delivery.
Sources:
...
PARI and Kamada Announce Positive Intermediate Phase I Results for
Inhaled Alpha-1 Antitrypsin
... liquid medications via a vibrating,
perforated membrane. Compared to other
nebulizer systems, eFlow can
produce aerosols with a very high density of active ... PARI Pharma provides comprehensive inhalation drug development,
including
nebulizer formulation development and optimization, CMC,
analytics, aerosol ...
Gilead Announces Presentation of Positive Phase III Data on
Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis
... in the United States
and Europe.
About PARI and the eFlow Electronic
nebulizer
Aztreonam lysine is delivered through a novel inhalation device,
the ... developed by PARI Pharma GmbH. The
eFlow is an electronic, portable
nebulizer that enables efficient
aerosolization of liquid medications via a ...
Gilead Announces Achievement of Primary Efficacy Endpoint in Second
Phase III Study of Aztreonam Lysine for Inhalation in Patients With
Cystic Fibrosis
... the United States and
Europe.
About PARI Pharma and the eFlow Electronic
nebulizer
Aztreonam lysine for inhalation is delivered by a novel
inhalation ... Nebulizer, developed by
PARI Pharma GmbH. eFlow is a quiet, portable
nebulizer that enables
efficient aerosolization of liquid medications via a ...
PARI Pharma Presents Study Results of Sinus Delivery and Inhaled
Liposomal Ciclosporin A at European Cystic Fibrosis Conference
... optimized to advanced delivery platforms, such as
eFlow.
Focusing on comprehensive inhalation therapy development,
including optimized
nebulizer formulations, analytics, and aerosol
characterization, PARI Pharma has several clinical development
programs ongoing, either partnered or ....